You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 31, 2025

Claims for Patent: 9,441,047

✉ Email this page to a colleague

Summary for Patent: 9,441,047

Title:	Methods for improving asthma symptoms using benralizumab
Abstract:	Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
Inventor(s):	Ward; Christine (Gaithersburg, MD), Roskos; Lorin (Gaithersburg, MD), Wang; Bing (Gaithersburg, MD), Raible; Donald (Berwyn, PA)
Assignee:	ASTRAZENECA AB (Sodertaje, SE)
Application Number:	14/454,149
Patent Claims:	1. A method of treating asthma by improving an asthma control questionnaire-6 (ACQ-6) score in an adult asthmatic patient, comprising administering to the adult patient a dose of 30 mg once every four weeks for twelve weeks and then once every eight weeks of benralizumab or an antigen-binding fragment thereof, wherein the ACQ6 score is decreased by at least 0.5. 2. The method of claim 1, wherein the administration improves an asthma symptom in the patient. 3. The method of claim 2, wherein the asthma symptom is selected from the group consisting of night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, rescue medication use, daytime symptom frequency and severity, nighttime symptom frequency and severity, activity avoidance and limitation, asthma-related anxiety, and fatigue. 4. The method of claim 1, wherein the asthma is eosinophilic asthma. 5. The method of claim 1, wherein the patient has a blood eosinophil count of at least 300 cells/.mu.l. 6. The method of claim 1, wherein the patient uses high-dose inhaled corticosteroids (ICS). 7. The method of claim 1, wherein the patient uses long-acting .beta. agonists (LABA). 8. The method of claim 1, wherein the patient has a history of exacerbations. 9. The method of claim 1, wherein the benralizumab or antigen-binding fragment thereof is administered in addition to corticosteroid therapy.

Details for Patent 9,441,047

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Astrazeneca Ab	FASENRA	benralizumab	Injection	761070	November 14, 2017	9,441,047	2034-08-07
Astrazeneca Ab	FASENRA	benralizumab	Injection	761070	October 03, 2019	9,441,047	2034-08-07
Astrazeneca Ab	FASENRA	benralizumab	Injection	761070	April 05, 2024	9,441,047	2034-08-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.